Phase 3 Alogliptin Pediatric Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

Also called NCT02856113

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02856113
  • WHO UTN U1111-1174-1923
  • EudraCT 2015-000208-25
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Israel, Italy, Mexico, Poland, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02856113. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-14 (actual); primary completion 2021-08-06 (actual). Results posted on 2022-10-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Alogliptin Pediatric Study
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Alogliptin Benzoate
Intervention (Drug)
Placebo
Lead sponsor
Takeda (class: industry)
Collaborator
Takeda Development Center Americas, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02856113
Content hash
21b47fcda0d0335548c4eb13d159aef0addc6a43d942348f03d2850b9c6c95e3